Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2018 August;109(4) > Minerva Medica 2018 August;109(4):280-4

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Medica 2018 August;109(4):280-4

DOI: 10.23736/S0026-4806.18.05572-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Benign prostatic hypertrophy: Pycnogenol® supplementation improves prostate symptoms and residual bladder volume

Andrea LEDDA 1, 2, Gianni BELCARO 1, 2 , Beatrice FERAGALLI 1, 2, Umberto CORNELLI 1, 2, Mark DUGALL 1, 2, Marcello CORSI 1, 2, Maria R. CESARONE 1, 2

1 IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy; 2 International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy


PDF


BACKGROUND: The aim of this study was to evaluate the efficacy of Pycnogenol® supplementation in terms of safety and tolerability in the setting of preclinical or borderline, initial symptoms of benign prostatic hyperthrophy (BPH), in otherwise healthy subjects, using Pycnogenol® over a period of 60 days.
METHODS: Seventy-five healthy men with symptoms and signs of initial BPH were included. The subjects were divided into three groups: 1) control group using only the standard management (SM); 2) a group using SM plus Pycnogenol® 150 mg/day; 3) a group using standard pharmacological management.
RESULTS: BPH symptoms like emptying, frequency, intermittency, urgency, weak flow, straining, nocturia, were all significantly improved with Pycnogenol® (P<0.05) and the difference with both control groups was statistically significant (P<0.05).
CONCLUSIONS: Pycnogenol® may be an important option for self-management of BPH in otherwise healthy men.


KEY WORDS: Prostatic hyperthrophy - Dietary supplements - Prostate - Pycnogenol® - Nocturia

inizio pagina